

1 **Title: BRIEF COMMUNICATION:**

2 **High level of Anti SARS-Co-V2 RBD Antibody one year post booster vaccine hospital**

3 **workers in Indonesia; Was second booster needed?**

4

5 **Short Title: High Level of Anti SARSCoV2-RBD Antibody Level among Healthcare Worker,**

6 **Booster or Not?**

7

8 **AUTHORS**

9 **Amila Hanifan Muslimah¹, Marita Restie Tiara², Hofiya Djauhari², Hafizh Dewantara¹,**

10 **Evan Susandi¹, Agnes Rengga Indrati³, Bacht Alisjahbana^{1,2}, Arto Yuwono Soeroto¹, Rudi**

11 **Wisaksana^{1*}**

12 ¹Department of Internal Medicine, Hasan Sadikin General Hospital, Faculty of Medicine,

13 Universitas Padjadjaran, Bandung, Indonesia

14 ²Research Center for Care and Control of Infectious Disease, Universitas Padjadjaran, Bandung,

15 West Java, Indonesia

16 ³Department of Clinical Pathology, Hasan Sadikin General Hospital, Faculty of Medicine,

17 Universitas Padjadjaran, Bandung, West Java, Indonesia

18

19 **Corresponding author:**

20 Rudi Wisaksana

21 **Department Of Internal Medicine, Universitas Padjadjaran, Bandung, Indonesia.**

22 Jl. Pasteur No.38, Pasteur, Sukajadi, Bandung City, West Java, Jawa Barat 40161

23 E-mail : rudi.wisaksana@unpad.ac.id

24 **Abstract: 272 words**

25 **Word Count: 2739 words**

26 **Figure 1**

27 **Table 1**

28 **CONFLICT OF INTEREST**

29 None

30 **ETHICAL APPROVAL**

31 Ethical clearance was provided by the Ethical Research Committee of Hasan Sadikin General Hospital (Number:

32 LB.02.01/X.6.5/117/2022)

33 **DATA AVAILABILITY**

34 The data used to support the findings of this study were included in the article.

35 **Contributorship Statement**

36 Amila Hanifan Muslimah: conceptualization, data curation, investigation, writing—original draft, writing— review,
37 and editing.

38 Rudi Wisaksana: conceptualization, data curation, investigation, writing— original draft, writing—review, editing,
39 validation, and supervision.

40 Marita Restie Tiara: conceptualization, data curation, investigation, writing-review, editing, validation, and
41 supervision.

42 Hafizh Dewantara: conceptualization, data curation, investigation.

43 Hofiya Djahuri: data curation, supervising laboratory work, conceptualization, investigation.

44 Evan Susandi : data curation, statistician, conceptualization, investigation.

45 Bachti Alisjahbana: conceptualization, investigation, writing—review

46 Arto Yuwono Soeroto: conceptualization, writing— original draft ,writing—review, editing, validation, authorization
47 and supervision.

48 Agnes Rengga Indrati: conceptualization, data curation, investigation, writing—review, editing, validation, and
49 supervision.

50

51 **ABSTRACT**

52 Healthcare workers in Indonesia acquired a complete 2 doses of Sinovac in early 2021 and first booster dose of
53 Moderna in July 2021. In August 2022, the ministry of health prioritized healthcare workers to acquire the second
54 booster dose of Moderna as antibody levels from the year before may have waned. We conducted a sequential
55 serosurvey aimed to determine the level of SARS CoV2 S-RBD antibody reached by the first vaccine, after the first
56 booster, and before the second booster to understand the dynamics of the antibody level. COVID-19 antibody test was
57 conducted using the FastBioRBD™ test with a maximum limit detection level of 4000 BAU/mL. First serosurvey
58 which was conducted in June 2021, one to six months after Sinovac vaccination, showed a median antibody level of
59 41.4 BAU/mL (IQR 10 – 629.4 BAU/mL). The second serosurvey was conducted one month (August 2021) after the
60 first Moderna booster vaccine, and showed a median level of 4000 BAU/mL (IQR 3081 – 4000 BAU/mL). While the
61 last serosurvey conducted a year (August 2022) after the booster, showed 4000 BAU/mL (IQR 4000 – 4000 BAU/mL).
62 Only 39 (11.9%) healthcare workers have antibody levels below the maximum level of 4000 BAU./mL We did not
63 see the waning of antibody levels among healthcare workers approximately 1 year after the booster. It increases
64 perhaps due to the natural infection caused by the omicron variant outbreak in early 2022. Based on this fact, we
65 suggest considering if the second booster dose is really necessary. The limited vaccine supply can better be given to
66 the person or other high-risk groups of patients who has a low level of antibody based on serological testing.

67

68 **Introduction**

69 SARS-CoV-2 infection has become a health problem worldwide, including in Indonesia. (1) Presence of anti-SARS-
70 CoV-2 antibody post-infection or due to vaccination has been confirmed to provide some protection against infection
71 and even more against severe COVID-19 disease. (2) Vaccination is therefore mandatory. However, current evidence
72 is still lacking about how many boosters are necessary for healthcare workers and the community at large. It is even
73 more difficult to determine because anti-SARS-CoV2 antibody level does affect by the type of vaccine we received,
74 exposure to natural infection as well as time since last vaccination/exposure, and internal factors like age and co-
75 morbidity. (3,4)

76 Healthcare workers were greatly affected during the first wave in 2020 and the Delta strain of SARS CoV-2 outbreak
77 in July-September 2021. Our healthcare workers acquired complete 2 doses of Sinovac vaccine from January to June

78 2021. Sinovac was chosen as the vaccine used for healthcare workers because it was most readily available in
79 Indonesia at that time. Next, they acquire Moderna Booster in August 2021. During the Omicron outbreak in early
80 2022, many health care workers were also infected with COVID-19 but no severe infection was rarely observed. In
81 July 2022, the Indonesian Ministry of Health decided to prioritize a second mRNA vaccine for healthcare workers in
82 Indonesia. (5,6)

83 With the vaccine scheme that we acquired and the periodic exposures to COVID-19 during outbreaks, we came to
84 wonder how high is our anti RBD-Level? And, is this second booster really necessary? Information about the level of
85 Anti SARSCoV2-SRBD antibody can assist in evaluating the need for additional vaccination. (7) This study aims to
86 describe the SARS CoV2 S-RBD antibody level among Hospital Workers in three consecutive serosurveys at different
87 time points which can provide information on whether a booster is necessary.

88

89 **Materials and methods**

90 This research was conducted at Hasan Sadikin General Hospital as the top referral hospital for COVID-19 in West
91 Java, Indonesia, with high exposure of COVID-19 infection healthcare workers during the pandemic. This study
92 received approval from the Health Research Ethics Committee of Hasan Sadikin General Hospital Number
93 LB.02.01/X.6.5/117/2022. It is a single-center, observational analysis study with a prospective design using primary
94 data examining levels of SARS CoV 2 IgG S RBD antibody in hospital healthcare workers. Data consisted of basic
95 participant information from interviews and results of antibody levels for SARS-COV-2 IgG S-RBD. All participants
96 were vaccinated using Sinovac in the months January-June 2021.

97

98 Our first serosurvey was conducted in July 2021, right before the third vaccine dose or the first booster using the
99 Moderna vaccine. The second serosurvey was conducted in August 2021, one month after the provision of the first
100 Moderna booster Vaccine. The third serosurvey was conducted in August 2022, 12 months after the first Moderna
101 booster, right before the second Moderna booster that was programmed by the Ministry of Health.

102

103 Eligible participants were health workers of Hasan Sadikin General hospital collected by voluntary participation. All
104 participants were vaccinated with the complete two doses of the inactivated virus vaccine (Sinovac) and one booster

105 dose of mRNA-1273 (Moderna) full dose. This study used a convenience sampling method. All hospital staff who
106 followed these vaccination schemes and were willing to participate in the study were included in the survey.

107
108 We use the following operational definition. Physicians were all MDs, mostly specialists but also included general
109 practitioner working in the hospital. COVID-19 wards were areas that had the highest risk of spreading COVID-19,
110 including COVID-19 intensive care, general care, and emergency isolation room. History of close contact with
111 confirmed cases were face-to-face contact with probable cases or confirmed cases within one-meter radius and 15
112 minutes or more, direct physical touch with probable or confirmed cases, or people who provided direct care to
113 probable or confirmed cases without using standard personal protective equipment. Last COVID-19 infections (having
114 previous COVID-19 infections in between surveys) were a person who has positive RT-PCR results or rapid antigen
115 resulta with at least three symptoms of COVID-19 infection based on the interview.

116
117 Determination of anti-SARS-CoV2 S-RBD Antibody uses a point of care quantitative immunochromatographic assay
118 (FastBioRBD™) produced by Wondfo, Guangzhou Biotech, China which was rebranded for distribution by PT
119 Biofarma, Indonesia (Persero). This equipment has a value range between 1 to 200 Arbitrary Unit (AU) where 1 is
120 regarded as the minimal level for being seropositive. We later multiplied the result by 20 to obtain the standard WHO
121 binding antibody unit (BAU). Therefore, 20 BAU/mL was the bottom limit for seropositivity, while the maximum
122 detection limit was 4000 BAU/mL. A similar fluorescent immunoassay test (Wondfo Finecare anti-RBD) has been
123 utilized and tested in Qatar. (8). To validate the FastBioRBD™ test, 71 randomly selected samples were tested using
124 the GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit (Genscript Biotech, Leiden, Netherlands).
125 Briefly, serum samples as well as negative and positive controls were diluted 1:10 in sample dilution buffer, mixed
126 1:1 with HRP-RBD working solution, and incubated at 37 °C for 30 min. For more information sees in reference (9).

127
128 The baseline characteristics of participants described were factors that might influence SARS CoV2 S-RBD antibody
129 level, which was age, gender, occupation, comorbidity, last COVID-19 infection, work zone, history of close contact,
130 and levels of SARS-CoV-2 Ig G S-RBD. Data on baseline characteristic were obtained based on information from

131 the interview with a validated questionnaire. Anti-SARS CoV2 S-RBD antibody level was described in the descriptive
132 table as well in graphical form.

133

134 Results

135 On the first survey, we enrolled 570 person during the first booster vaccination day. After blood collection, these
136 subjects directly acquired the first booster of Moderna (full dose). One month after this first booster we enrolled 355
137 person in the second survey. One year after the first booster, we enrolled and collect serum samples from 330 persons
138 in the third survey right before the second booster of Moderna (figure). Participants' demography and characteristics
139 are summarized in the Table.

140

141 **Table. Baseline Characteristics of Participants**

142

Variables	First Survey (n=570)	Second Survey (n=355)	Third Survey (n=330)
Gender			
Male, n (%)	215 (38%)	120 (34%)	112 (34%)
Female, n (%)	355 (62%)	235 (66%)	218 (66%)
Age Category, median (IQR)	38 (32-50)	40 (33-52)	41 (34-52)
18 – 30 y.o, n (%)	88 (15.5%)	55 (15.5%)	39 (12%)
31 – 40 y.o, n (%)	223 (39.1%)	130 (36.7%)	122 (36.9%)
41 – 50 y.o, n (%)	119 (20.7%)	72 (20.3%)	70 (21.2%)
51 – 60 y.o, n (%)	108 (18.9%)	69 (19.4%)	79 (23.9%)
>60 y.o, n (%)	33 (5.8%)	29 (8.1%)	20 (6%)
Occupation			
Doctors, n (%)	283 (49.6%)	208 (58%)	155 (46%) [^]
Non-Doctors, n (%)	287 (50.4%)	147 (42%)	175 (54%)
Work-zone, n (%)			
In COVID-19 ward	147 (25.8%)	119 (33.5%)	102 (30.9%)
Not in COVID-19 ward	254 (44.5%)	155 (43.7%)	134 (40.6%)
Administrative work	169 (29.7%)	81 (22.8%)	94 (28.5%)
History of Close contact with confirm case, n (%)	210 (36.8%)	15 (4.2%)	68 (20%)
Last COVID 19 infections (having previous COVID 19 infection in between survey), n (%)	127 (22,2%)	34 (9.5%)	124 (37.5%)
Antibody Level (Median, IQR) BAU/mL	41.4 (10 – 629.4)	4000 (3081 – 4000)	4000 (4000 – 4000)
Antibody Level Classification			
≥4000 BAU/mL	0 (0%)	205 (57.7%)	291 (88.1%)
< 4000 BAU /mL	570 (100%)	150 (42.3%)	39 (11.9%)

143 **Notes: *n=frequency, %=percentage, ^ p value =0.05**

144

145 The median age of the participants was 41 (IQR 34 to 52) years old, and 46% were practicing physicians. 64 (19.3
146 %) were specialists, and 91 (27.5%) were general physicians. Among the non-physician, 55 (16.6%) were nurses, 10
147 (3.03 %) were laboratory staff and 73 (22.1%) were the administrative staff. Most of the participants belong to the
148 non-covid ward group (254, 44.5%), while 147 (25.8%) were stationed and routinely care for COVID-19 patients in
149 the ward.

150

151 During the first survey, the SARS CoV2 S-RBD antibody level median was 41,4 BAU/mL (Range 0.2 – 2.049.6
152 BAU/mL). One hundred eight (32.7 %) participants showed negative results for SARS-CoV-2 S-RBD antibody
153 (BAU/mL < 20) and 175 (30.7%) participants did not reach the median value (< 41.4 BAU/mL). No participant
154 reached a maximum detection level of 4000 BAU/mL. From the interview, 127 (%) reported having confirmed
155 COVID-19 illness since the beginning of the Pandemic.

156


157 In the second survey, we observed a median of 4000 BAU/mL (Range 840,4 – 4000). One hundred fifty (42.3%)
158 participants had antibody levels below the maximum detection level of 4000 BAU/mL. No participant showed
159 negative anti-SARS CoV2-SRBD. Within one month duration between the first and second survey, 34 participants
160 reported having confirmed covid illness.

161

162 In the third survey, we obtained a median SARS CoV2 S-RBD antibody level of 4000 BAU/mL (range 144,8 – 4000
163 BAU/mL). In this survey 124 (37.5%) participants reported having confirmed COVID-19 illness within one year
164 between the second and the third survey. The distribution of antibody levels based on the time of examination can be
165 seen in the Figure.

166

167 Individuals with maximum antibody levels >4000 BAU/mL one month after 3rd vaccination had more COVID-19
168 infections after 3rd vaccination, with 57 participants (58.2%) and antibody levels >4000 BAU/mL twelve months after
169 3rd vaccination having more COVID-19 infections with 106 participants (85.5%). The less infection in the second
170 survey probably was due to the shorter time interval between the first survey and the second survey.



171
172

173 A bivariate analysis test was performed on factors potentially related to antibody levels on the last serosurvey.
 174 Bivariate analysis showed that being a physician was associated with a lower SARS CoV2 S-RBD antibody levels.
 175 Doctors have lower antibody levels (4000, Range 460-4000 BAU/mL) compared to non-doctors professions (4000,
 176 Range 145-4000 BAU/mL) ($p=0.05$). The multivariate analysis gave the same result, which was that being a doctor
 177 was a factor that had a significant result (adjusted OR 0.512 (95% CI 0.258-1.015) S1Table. Antibody levels twelve
 178 months after the third vaccination did not reflect a protective effect against COVID infection 19.

179

180 Seventy-one randomly selected serum samples underwent validation tests with Genscript C-Pass. FastBioRBD™
 181 compared to C-Pass showed a correlation with r- value of 0.78 (95% CI 0.678-0.862) S2 Figure.

182

183 **Discussion**

184 We found an increasingly high antibody levels among healthcare workers in our hospital one year post booster. We
185 think that this was due to natural exposure throughout the pandemic. Many believe that the antibody level that has
186 been stimulated by the COVID-19 vaccine may gradually decline within several months (10,11). However, our
187 observation did not show this situation.

188

189 Antibody levels were examined in participants about six months after being vaccinated with two Sinovac vaccinations
190 shown to reach a marginal level. There is still a substantial proportion of participants who showed negative serology.

191 A study in Turkey conducted in March 2021 observing Anti-RBD antibody levels 28 days post two doses of the
192 Sinovac vaccine in 330 health workers showed that 99.4% of health workers had a seropositive result with a median
193 of 154.78 BAU/mL. While only thirty-two-point-four percent of participants have maximum antibody levels. (12)

194 Antibody examination on healthcare workers in Hasan Sadikin General Hospital has a median time of 5,5 months
195 after the second dose of Sinovac vaccination, thus showing lower results. This is similar to a study conducted by
196 Fonseca et al in Brazil, in September 2021, that antibody levels 6 months after two doses of the Sinovac vaccine lower
197 levels with a median of 66.7 BAU/mL and 16 (2%) participants became seronegative. (13) The difference of these
198 findings can also be affected by the local epidemic dynamics in each country/region. (14)

199

200 The increase in antibody levels one month after receiving the first booster of Moderna vaccination was expected. Over
201 half of the respondents showed a maximum readable level of RBD antibody in this survey. However, there were still
202 a few subjects who showed only a moderate increase in antibody response. Adding a booster of mRNA vaccine in
203 subjects who have acquired inactivated vaccine was shown to increase their antibody level. A study in Chile has shown
204 that the group of subjects who acquired two Sinovac vaccines and a booster with the BNT162b2 RNA vaccine had
205 higher antibody levels 1 month after the third vaccination compared to the group given two Sinovac vaccines and the
206 third vaccine with Sinovac. (15) Several studies have also shown the effect of the Moderna vaccine, which
207 demonstrates a higher antibody response than the BNT vaccine.(16,17)

208

209 The third survey was conducted in August 2022, one year after the last booster of the Moderna vaccine and after we
210 went through the Omicron outbreak in early 2022. In this survey, we found an even higher anti-RBD antibody level

211 among hospital staff and there were no signs of weaning of antibody level. The increased antibody level between the
212 second survey to the third survey was most probably due to COVID-19 exposure during the Omicron outbreak. The
213 result of our study is similar to the national serosurvey conducted in Indonesia. The Indonesian serosurvey has been
214 conducted routinely in October and November 2021 and July 2022. The serosurvey also reveals an increasing antibody
215 level in all communities in Indonesia. The vaccinated person has a higher antibody response than a non-vaccinated
216 person. (18,19) A similar study in Italy conducted in January-November 2021 also showed similar results where anti-
217 COVID RBD antibody increases months after receiving a booster vaccine. (20)

218
219 Our study showed that participants with high antibody levels experienced more COVID-19 infection. As we know
220 now from various reports, antibody level does not effectively prevent infection, especially with the new variant.
221 (21,22) But it significantly lowers the chances of having severe covid-19 illness. (23) The higher infection among
222 these groups could be due to their working environment or lifestyle which is already related to higher exposure to
223 COVID-19 since the beginning, therefore they have higher antibody response, and chances of new infection. Our data
224 and several other reports have consistently shown that (in developing countries) infections are mostly due to casual
225 contact rather than from the working environment. (24) Whereas casual contact was less affected by the hospital
226 protocol as well as national regulation.

227
228 Our study extensively uses the quantitative immunochromatographic assay which is easy to use and affordable. The
229 test uses a cassette-based dry reagent with a small portable reader which can be utilized in a point-of-care setting.
230 Compared to other tests, this test has good and acceptable validity. Our validation test of 71 samples with Genescript
231 C-Pass showed a good correlation results. The Subject who has maximum detection level has a more than 90% result
232 based on genescript SVNT assay had a sensitivity of 63.8%, specificity of 100%, positive predictive value of 100%,
233 and negative predictive value of 41.4%. A validation test in Qatar has selected 150 subject serum samples with r-
234 value of 0.7 (95% CI 0.60 to 0.80). (8)

235
236 Our study has some limitation. We collect the person invited to the survey based on the person who was willing to be
237 tested. Thus, the number of samples, especially on the second and the third survey may not represent the whole hospital

238 staff population. However, within our observation, we have represented the whole range of types of workers and
239 exposure levels. Information about the previous COVID-19 was collected through interview or self-reporting. This
240 method may not be the most accurate as there might be information bias. Although based on other reports, self-
241 reporting may lead to lower prevalence than registered reports. (18,19)

242

243 **Conclusion**

244 We did not find a waning of humoral immunity to COVID-19 among healthcare workers in our hospital. Most
245 probably this is due to the high transmission of SARS CoV2 and the outbreak of the omicron in early 2022. Most
246 healthcare workers have a very high level of SARS CoV2 S-RBD antibody level 12 months post third COVID-19
247 vaccine dose. Based on this result, we should consider if a fourth vaccine dose is necessary for all. To make efficient
248 use of the vaccine distributed, we suggest to incorporating antibody testing and only providing booster to those who
249 have lower anti-RBD Antibody level.

250

251 **CONFLICT OF INTEREST**

252 None

253 **ACKNOWLEDGEMENT**

254 We are grateful for the support from Wondfo, Guanzhou Biotech, China, and PT Biofarma Indonesia (Persero) for
255 providing the FastBioRBDtm fluorescent immunoassay reader and the rapid test reagents for our study. Thank you to
256 Research and Innovation Indonesian Institute (BRIN) for providing initial operational support for conducting the
257 study. We thank the director of Hasan Sadikin General Hospital for allowing this study to be conducted and the staff
258 of the hospital who participated in this study. We thank the Dean of the Medical Faculty of Padjadjaran University
259 who provide laboratory facilities for sample management and testing in this study.

260

261 **DATA AVAILABILITY**

262 The data used to support the findings of this study were included in the article.

263

264 **REFERENCES**

- 265 1. World Health Organization. Novel Coronavirus (COVID-19) Situation. 2022 Feb 25 [cited 25 February
266 2022]. Available from: <https://covid19.who.int/>.
- 267 2. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection
268 against COVID-19 in humans. *Nat Rev Immunol*. 2021;475–484.
- 269 3. Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy, et al. Spike-antibody waning
270 after second dose of BNT162b2 or ChAdOx1. *Lancet*. 2021;398(10298):385-387.
- 271 4. Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac,
272 and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre,
273 double-blind, randomised, placebo-controlled phase 2 clinical trials. *Lancet Infect Dis*. 2021;S1473-
274 3099(21):00681-2.
- 275 5. Minister of Health. Decree of the Minister of Health of the Republic of Indonesia. Technical Instructions for
276 the Implementation of Vaccination in the Context of Combating the 2019 Corona Virus Disease (Covid-19)
277 Pandemic;2022 [cited 20 February 2022]. Database: Management of Public Information on the Supreme
278 Audit Board [internet]. Available from: [https://peraturan.bpk.go.id/Home/Details/169665/permenkes-no-10-
279 tahun-2021](https://peraturan.bpk.go.id/Home/Details/169665/permenkes-no-10-tahun-2021).
- 280 6. Ministry of Health of the Republic of Indonesia. Circular Letter Number Hk.02.02/C/3615/2022 Concerning
281 the 2nd Booster Dose of Covid-19 Vaccination for Health Human Resources. Ministry of Health of the
282 Republic of Indonesia. 2022 July 28 [cited 30 July 2022]. Available from:
283 [https://www.kemkes.go.id/downloads/resources/download/lain/Surat-Edaran-Vaksinasi-COVID_19-Dosis-
284 Booster-2.pdf](https://www.kemkes.go.id/downloads/resources/download/lain/Surat-Edaran-Vaksinasi-COVID_19-Dosis-Booster-2.pdf).
- 285 7. Lo Sasso B, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, Ciaccio AM, Agnello L, Ciaccio
286 M. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine.
287 *Diagnostics (Basel)*. 2021;11(7):1135.c
- 288 8. Shurrab FM, Younes N, Al-Sadeq DW, Liu N, Qotba H, Laith J, Abu-Raddad LJ, Nasrallah GK. Performance
289 evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification
290 of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individu. *Int. J. Infect. Dis*. 2022; 118:132–
291 137.

- 292 9. GenScript. cPass SARS-CoV-2 Neutralization Antibody Detection Kit Instruction for Use. In: Nanjing
293 GenScript Diagnostics Technology Co. L, editor. 2022.
- 294 10. Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy, et al. Spike-antibody waning
295 after second dose of BNT162b2 or ChAdOx1. *Lancet*. 2021;398(10298):385-387.
- 296 11. Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac,
297 and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre,
298 double-blind, randomized, placebo-controlled phase 2 clinical trials. *Lancet Infect Dis*. 2021;S1473-
299 3099(21):00681-2.
- 300 12. Dinc HO, Saltoglu N, Can G, Balkan II, Budak B, Ozbey D, Caglar B, Karaali R, Mete B, Tuyji Tok Y,
301 Ersoy Y, Ahmet Kuskucu M, Midilli K, Ergin S, Kocazeybek BS. Inactive SARS-CoV-2 vaccine generates
302 high antibody responses in healthcare workers with and without prior infection. *Vaccine*. 2022;40(1):52-58.
- 303 13. Fonseca MHG, de Souza TFG, de Carvalho Araújo FM, de Andrade LOM. Dynamics of antibody response
304 to CoronaVac vaccine. *J Med Virol*. 2022;94(5):2139-2148.
- 305 14. Zimmermann P., Curtis N. Factors That Influence the Immune Response to Vaccination. *Cli Microbiol*
306 *Rev*. 2019;32(2):e00084-18.
- 307 15. Vargas, L., Valdivieso, N., Tempio, F. et al. Serological study of CoronaVac vaccine and booster doses in
308 Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. *BMC Med*. 2022; 20:216.
- 309 16. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response
310 following vaccination with BNT162b2 and mRNA-1273. *JAMA*. 2021;326(15):1533-1535.
- 311 17. Collier AY, Yu J, McMahan K, et al. Differential kinetics of immune responses elicited by Covid-19
312 vaccines. *N Engl J Med*. 2021;385(21):2010-2012.
- 313 18. Indonesian Health Ministry. National Survey Serology Results. 2022 March 18 [cited 24 January 2023] In:
314 COVID 19 Indonesia [Internet]: Jakarta: Indonesian Health Ministry. Available from :
315 [https://covid19.go.id/artikel/2022/03/18/hasil-survei-serologi-covid-19-di-indonesia-november-desember-](https://covid19.go.id/artikel/2022/03/18/hasil-survei-serologi-covid-19-di-indonesia-november-desember-2021)
316 [2021](https://covid19.go.id/artikel/2022/03/18/hasil-survei-serologi-covid-19-di-indonesia-november-desember-2021)

- 317 19. Indonesian Health Ministry. Third National Serology Survey. 2022 September [cited 24 January 2023] In:
318 Indonesian Health Ministry [Internet]: Jakarta: Indonesian Health Ministry. Available from :
319 <https://www.youtube.com/watch?v=cgESZbe9rC0>.
- 320 20. Lo Sasso B, Agnello L, Giglio RV, et al. Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies
321 before and after the third dose of the BNT162b2 vaccine. *Sci Rep.* 2022;12:8679.
- 322 21. Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. A Detailed Overview of Immune Escape, Antibody
323 Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants with Escape Mutations. *Front*
324 *Immunol.* 2022;9(13): 801522.
- 325 22. Cromer D et al. Neutralizing antibody titers as predictors of protection against SARS-CoV-2 variants and the
326 impact of boosting: a meta-analysis. *Lancet Microbe* 2022;3:e52–61.
- 327 23. Agrawal U et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters:
328 pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland,
329 Scotland, and Wales. *Lancet* 2022;400: 1305–20.
- 330 24. Yu HJ, Hu YF, Liu XX, Yao XQ, Wang QF, Liu LP, Yang D, Li DJ, Wang PG, He QQ. Household infection:
331 The predominant risk factor for close contacts of patients with COVID-19. *Travel Med Infect Dis.* 2020;
332 36:101809.
- 333
- 334

335 **Figure**

336 **Fig 1. SARS CoV 2 S RBD Antibody Level Across Serosurveys**

337

338 **Tables**

339 **Table 1. Baseline Characteristics of Research Subjects**

340

341 **Supplementary**

342 **S1 Table. Multivariate Analysis of Antibody Levels 12 Months after The Third Vaccination**

343

344 **S2 Figure. Surrogate Virus Neutralization Test (SVNT) Correlation with Anti-RBD FastBioRBD™**
345 **in Participants after 12 Months of Third Vaccination**

346

347 **REFERENCES**

- 348 1. World Health Organization. Novel Coronavirus (COVID-19) Situation. 2022 Feb 25 [cited 25 February
349 2022]. Available from: <https://covid19.who.int/>.
- 350 2. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection
351 against COVID-19 in humans. *Nat Rev Immunol*. 2021;475–484.
- 352 3. Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy, et al. Spike-antibody waning
353 after second dose of BNT162b2 or ChAdOx1. *Lancet*. 2021;398(10298):385-387.
- 354 4. Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac,
355 and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre,
356 double-blind, randomised, placebo-controlled phase 2 clinical trials. *Lancet Infect Dis*. 2021;S1473-
357 3099(21):00681-2.
- 358 5. Minister of Health. Decree of the Minister of Health of the Republic of Indonesia. Technical Instructions for
359 the Implementation of Vaccination in the Context of Combating the 2019 Corona Virus Disease (Covid-19)
360 Pandemic;2022 [cited 20 February 2022]. Database: Management of Public Information on the Supreme
361 Audit Board [internet]. Available from: <https://peraturan.bpk.go.id/Home/Details/169665/permenkes-no-10-tahun-2021>.
- 362

- 363 6. Ministry of Health of the Republic of Indonesia. Circular Letter Number Hk.02.02/C/3615/2022 Concerning
364 the 2nd Booster Dose of Covid-19 Vaccination for Health Human Resources. Ministry of Health of the
365 Republic of Indonesia. 2022 July 28 [cited 30 July 2022]. Available from:
366 [https://www.kemkes.go.id/downloads/resources/download/lain/Surat-Edaran-Vaksinasi-COVID_19-Dosis-](https://www.kemkes.go.id/downloads/resources/download/lain/Surat-Edaran-Vaksinasi-COVID_19-Dosis-Booster-2.pdf)
367 [Booster-2.pdf](https://www.kemkes.go.id/downloads/resources/download/lain/Surat-Edaran-Vaksinasi-COVID_19-Dosis-Booster-2.pdf).
- 368 7. Lo Sasso B, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, Ciaccio AM, Agnello L, Ciaccio
369 M. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine.
370 *Diagnostics (Basel)*. 2021 Jun 22;11(7):1135.
- 371 8. Shurrab FM, Younes N, Al-Sadeq DW, Liu N, Qotba H, Laith J. Abu-Raddad LJ, Nasrallah GK. Performance
372 evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification
373 of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individu. *Int. J. Infect. Dis.* 2022; 118:132–
374 137.
- 375 9. GenScript. cPass SARS-CoV-2 Neutralization Antibody Detection Kit Instruction for Use. In: Nanjing
376 GenScript Diagnostics Technology Co. L, editor. 2022.
- 377 10. Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy, et al. Spike-antibody waning
378 after second dose of BNT162b2 or ChAdOx1. *Lancet*. 2021;398(10298):385-387.
- 379 11. Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac,
380 and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre,
381 double-blind, randomized, placebo-controlled phase 2 clinical trials. *Lancet Infect Dis*. 2021;S1473-
382 3099(21):00681-2.
- 383 12. Dinc HO, Saltoglu N, Can G, Balkan II, Budak B, Ozbey D, Caglar B, Karaali R, Mete B, Tuyji Tok Y,
384 Ersoy Y, Ahmet Kuskucu M, Midilli K, Ergin S, Kocazeybek BS. Inactive SARS-CoV-2 vaccine generates
385 high antibody responses in healthcare workers with and without prior infection. *Vaccine*. 2022;40(1):52-58.
- 386 13. Fonseca MHG, de Souza TFG, de Carvalho Araújo FM, de Andrade LOM. Dynamics of antibody response
387 to CoronaVac vaccine. *J Med Virol*. 2022;94(5):2139-2148.
- 388 14. Zimmermann P., Curtis N. Factors That Influence the Immune Response to Vaccination. *Cli Microbiol*
389 *Rev*. 2019;32(2):e00084-18.

- 390 15. Vargas, L., Valdivieso, N., Tempio, F. et al. Serological study of CoronaVac vaccine and booster doses in
391 Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. *BMC Med.* 2022; 20:216.
- 392 16. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response
393 following vaccination with BNT162b2 and mRNA-1273. *JAMA.* 2021;326(15):1533-1535.
- 394 17. Collier AY, Yu J, McMahan K, et al. Differential kinetics of immune responses elicited by Covid-19
395 vaccines. *N Engl J Med.* 2021;385(21):2010-2012.
- 396 18. Indonesian Health Ministry. National Survey Serology Results. 2022 March 18 [cited 24 January 2023] In:
397 COVID 19 Indonesia [Internet]: Jakarta: Indonesian Health Ministry. Available from :
398 [https://covid19.go.id/artikel/2022/03/18/hasil-survei-serologi-covid-19-di-indonesia-november-desember-](https://covid19.go.id/artikel/2022/03/18/hasil-survei-serologi-covid-19-di-indonesia-november-desember-2021)
399 [2021](https://covid19.go.id/artikel/2022/03/18/hasil-survei-serologi-covid-19-di-indonesia-november-desember-2021)
- 400 19. Indonesian Health Ministry. Third National Serology Survey. 2022 September [cited 24 January 2023] In:
401 Indonesian Health Ministry [Internet]: Jakarta: Indonesian Health Ministry. Available from :
402 <https://www.youtube.com/watch?v=cgESZbe9rC0>.
- 403 20. Lo Sasso B, Agnello L, Giglio RV, et al. Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies
404 before and after the third dose of the BNT162b2 vaccine. *Sci Rep.* 2022;12:8679.
- 405 21. Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. A Detailed Overview of Immune Escape, Antibody
406 Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants with Escape Mutations. *Front*
407 *Immunol.* 2022;9(13): 801522.
- 408 22. Cromer D et al. Neutralizing antibody titers as predictors of protection against SARS-CoV-2 variants and the
409 impact of boosting: a meta-analysis. *Lancet Microbe* 2022;3:e52–61.
- 410 23. Agrawal U et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters:
411 pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland,
412 Scotland, and Wales. *Lancet* 2022;400: 1305–20.
- 413 24. Yu HJ, Hu YF, Liu XX, Yao XQ, Wang QF, Liu LP, Yang D, Li DJ, Wang PG, He QQ. Household infection:
414 The predominant risk factor for close contacts of patients with COVID-19. *Travel Med Infect Dis.* 2020;
415 36:101809.
- 416

417 **Fig 1. SARS CoV 2 S RBD Antibody Level Across Serosurveys**

418 Sequential serosurvey of SARS CoV2 S-RBD antibody before first booster Moderna, one month after first booster Moderna, and 12 months after
419 first booster Moderna. Most healthcare workers have very high level of SARS CoV2 S-RBD antibody level 12 months post third COVID 19 vaccine
420 dose. Second Moderna booster was given right after the blood taking off the third survey.

421

422




Fig 1. SARS CoV 2 S RBD Antibody Level